Clinical Trials Browser

Imatinib Mesylate × Dermatologic × Clear all

NCT00421317 2026-03-13

O-Mel-Inib

Phase 2 Terminated

Melanoma

NCT01046487 2026-03-13

PALANGI3

Phase 1 Completed

DermatologicGastrointestinalSarcoma

Uveal Melanoma, Chordoma, Carcinoma, Adenoid Cystic, Neoplasms, Desmoid Tumors, Dermatofibrosarcoma, Gastrointestinal Stromal Tumors

NCT04598009 2025-09-03

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Phase 2 Recruiting

Melanoma

NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Phase 1/2 Unknown

Melanoma

NCT00667953 2023-03-30

Study of Temzolomide and Gleevec in Advanced Melanoma

Phase 1/2 Terminated

32 enrolled 8 charts

Melanoma

NCT00027586 2018-10-31

Imatinib Mesylate in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma, Skin Neoplasms

NCT00074308 2018-06-20

Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers

Phase 1/2 Completed

40 enrolled 10 charts

Melanoma

NCT02812693 2018-04-05

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Phase 1/2 Withdrawn

Melanoma

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Phase 2 Completed

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT00470470 2014-12-23

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

30 enrolled 7 charts

Melanoma

NCT00402662 2013-12-18

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

Phase 2 Terminated

Melanoma

NCT00068783 2013-02-28

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Phase 2 Completed

Carcinoma, Merkel Cell

NCT01782508 2013-02-04

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Phase 2 Unknown

Melanoma

NCT00881049 2011-01-17

Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma